IL5 Report: Understanding the Homozygous IL-5 Gene Variant

By Dan Purser MD

If your genetic screening reveals a **homozygous high-producing single nucleotide polymorphism (SNP) in your IL5 gene** (such as the *TT* genotype at the *IL5* C-703T locus), it means you have inherited two identical copies of a genetic sequence that overproduces Interleukin-5 (IL-5).

This patient report covers the clinical footprint of this variant, explores the current landscape of FDA-approved biologic therapies, and examines how advanced cellular therapies—specifically the **VARS Triad** (VARS Glutathione, VARS SOD, and VARS Catalase)—can be integrated into your treatment plan as a main-course or adjuvant therapy.

The Core Problem: Eosinophil Hyper-Activation & The Oxidative Burst

IL-5 is the primary cytokine responsible for the growth, activation, and survival of **eosinophils** (a specialized type of white blood cell). When you are homozygous for a high-producing IL-5 variant, your body keeps the chemical faucet turned "on." This causes a continuous over-recruitment of eosinophils into soft tissues, triggering chronic **Type 2 (T2) high inflammation**.

However, the damage isn't just driven by the physical presence of these cells. When eosinophils gather in your lungs, sinuses, or digestive tract, they undergo an **"oxidative burst."** They release immense amounts of highly destructive reactive oxygen species (ROS)—such as superoxide radicals and hydrogen peroxide. This creates an environment of severe localized **oxidative stress** that tears through healthy cell membranes, degrades tissue, and causes permanent structural changes like airway scarring and polyps.

The Pathological Loop: Excess IL-5 recruits eosinophils Eosinophils unleash an oxidative burst Free radicals damage tissue and activate cellular stress signals Cellular stress signals call for even more inflammatory cytokines.

Associated Diseases and Symptoms

This relentless cycle of genetic overproduction and oxidative damage typically manifests as one or more **Eosinophil-Associated Diseases (EADs)**:

- **Severe Eosinophilic Asthma:** Characterized by chronic wheezing, airway remodeling (scarring), a mucus-heavy cough, and sudden, severe attacks that frequently resist standard steroid inhalers.
- **Chronic Rhinosinusitis with Nasal Polyps (CRSwNP):** Severe tissue swelling in the nasal cavities that leads to painful facial pressure, structural blockages (polyps), and a partial or total loss of smell and taste.
- **Eosinophilic Esophagitis (EoE):** Dense accumulation of eosinophils in the food pipe, causing painful or difficult swallowing (dysphagia), severe acid reflux, and instances of food getting stuck.

Comprehensive Management of Homozygous IL-5 High-Producing Variants through Biologics and the VARS Antioxidant Triad

Macro-Level Strategy: FDA-Approved Biologic Therapies

To interrupt this pathway at the genetic and molecular level, modern medicine utilizes targeted monoclonal antibodies (biologics). These therapies are designed to bind directly to the excess IL-5 signaling molecules or their respective docking receptors.

Anti-IL-5 and Anti-IL-5Rα Biologics

- **Mepolizumab (Nucala) & Reslizumab (Cinqair):** These biologics act like specialized molecular sponges. They capture the excess floating IL-5 proteins before they can reach and wake up your eosinophils.
- **Benralizumab (Fasenra):** This drug targets the IL-5 receptor alpha (IL-5R-Alpha) docking station directly on the eosinophil surface, flagging the overabundant cells so your natural immune system can safely clear them away.
- **Depemokimab (Exdensur):** Approved as an ultra-long-acting anti-IL-5 formulation, this advanced biologic offers sustained suppression of the eosinophilic pathway with a highly convenient dosing schedule of just **two injections per year** (once every 6 months).

Upstream and Cross-Pathway Biologics

- **Tezepelumab (Tezspire):** An anti-TSLP biologic that acts further upstream, cutting off the foundational alarm signals released by irritated airway linings before they can stimulate IL-5 production.
- **Lirentelimab:** An anti-Siglec-8 biologic utilized as an adjunct to directly downregulate and deplete active eosinophils and mast cells in severe tissue-specific inflammation.

Micro-Level Strategy: The VARS Antioxidant Triad

While biologics excel at reducing the overall "army" of eosinophils, they do not automatically mop up the toxic biochemical waste (free radicals) left behind by existing tissue inflammation. This is where the **VARS Triad** comes into play.

The VARS formulation utilizes a specialized, highly absorbable delivery system (designed to survive digestion and optimize cellular uptake) to supply your body with its three core, primary intracellular antioxidant enzymes. Used as a main-course therapy for those seeking non-pharmaceutical management, or as an adjuvant alongside biologics, the triad systematically dismantles the oxidative burst:



Supported by VARS Glutathione to prevent lipid cell wall damage

1. VARS Superoxide Dismutase (SOD)

- **The Role:** SOD functions as your immune system's cellular "first responder."
- **The Benefit:** It immediately intercepts the highly volatile superoxide radicals generated during an eosinophilic flare-up, converting them into a milder compound: hydrogen peroxide.

2. VARS Catalase

- **The Role:** Catalase acts as the master "firefighter" enzyme.
- **The Benefit:** Hydrogen peroxide is still toxic to your respiratory and sinus linings. Catalase instantly steps in to break it down into completely harmless water (H^2O) and oxygen (O^2), preventing it from degrading into ultra-destructive hydroxyl radicals.

3. VARS Glutathione

- **The Role:** Known as the "master antioxidant," this tripeptide protects the physical architecture of your cells.
- **The Benefit:** Eosinophilic inflammation causes "lipid peroxidation"—the literal rusting and breaking down of your cell walls. VARS Glutathione shields the cell membranes, supports liver-led detoxification of inflammatory byproducts, and suppresses *NF-κB*, the primary cellular genetic switch that tells your body to manufacture more inflammatory cytokines.

Intertwining the Two Approaches: The Dual-Pronged Protocol

For patients with a homozygous high-producing IL-5 profile, combining FDA-approved biologics with the VARS Triad creates a comprehensive macro-and-micro clinical synergy.

1. **The Biologic Hand-Off:** The biologic (e.g., Benralizumab or ultra-long-acting Depemokimab) handles the macro-genetics. It dramatically slashes the overproduction of eosinophils arriving from the bone marrow.
2. **The VARS Triad Clean-Up:** The remaining localized eosinophils and tissue-bound immune cells will still attempt to fire off oxidative bursts. The VARS Triad acts as a cellular shield, neutralizing these free radicals in real-time.

By quenching the oxidative stress, the VARS Triad prevents the tissue scarring and polyp regrowth that can occur even when a patient is on a biologic. Furthermore, downregulating oxidative stress helps preserve the integrity of your tissue receptors, which can actively **enhance your body's responsiveness to the biologic itself** and reduce systemic cortisone or steroid dependence.

Diagrams

Diagram 1 – Disease Overview & Attack on Key Body Parts



Diagram 2 – The Pathological Loop: IL-5 → Eosinophils → Oxidative Burst



Diagram 3 – Treatment Options + VARS Triad Mechanism



References

Protocol Matrix: Biologics vs. VARS Triad

Feature	FDA-Approved Biologics (e.g., Depemokimab, Fasenra)	VARS Triad (Glutathione, SOD, Catalase)
Primary Target	The IL-5 signaling protein and the IL-5Ralpha cellular receptor.	Intracellular free radicals, superoxide, and lipid peroxides.
Mechanism	**Macro-Control:** Shuts down the genetic	**Micro-Shield:** Neutralizes the oxidative burst and protects cellular walls from tissue degradation.

Feature	FDA-Approved Biologics (e.g., Depemokimab, Fasenra)	VARS Triad (Glutathione, SOD, Catalase)
	recruitment and survival of eosinophils.	
Clinical Value	Prevents systemic flare-ups, asthma hospitalizations, and severe tissue eosinophilia.	Reverses local oxidative stress, mitigates tissue scarring/remodeling, and turns off inflammatory switches (*NF-κB*).
Integration Status	Main course for moderate-to-severe clinical presentations.	Ideal standalone regimen for mild/moderate cases, or vital adjuvant therapy to optimize biologic outcomes.

References

1. Hameed RM, Abood HA, Ahmed MM. Systematic review and meta-analysis of the association between C-746T and C-703T polymorphisms of the interleukin-5 gene and asthma. *Biomed Biotechnol Res J*. 2020;4(4):323-329.
2. Pelaia C, Paoletti G, Pelaia G, et al. Interleukin-5 in the pathophysiology of severe asthma. *Front Physiol*. 2019;10:1514.
3. Zhang L, Overeem AJ, van Schadewijk A, et al. Role of IL-5 in eosinophil-associated diseases and prospects for multi-target therapy. *Front Immunol*. 2026;17:1817893.
4. Asthma and Allergy Foundation of America. Biologics for the treatment of asthma. AAFA website. Updated March 2026. Accessed June 2026.
5. Food and Drug Administration. FDA approves Exdensur (depemokimab-ulaa) for severe persistent eosinophilic asthma. FDA Drug Safety Communication. December 2025.
6. National Institutes of Health. The role of oxidative stress in the pathogenesis of childhood asthma: A comprehensive review. *PMC*. 2025;12468837.
7. Al-Sawalha N, et al. Antioxidant enzyme profiles (SOD, Catalase, and Glutathione Peroxidase) in mucosal inflammatory disorders driven by T2-high cytokine pathways. *Int Immunopharmacol*. 2024;112:109210.
   Primary cytokine responsible for growth, activation, and survival of eosinophils.